Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | MMP3 | P08254 | 2/20 | 0.61 |
| ▸ | ABAT | P80404 | 1/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3626838 | 0.98 | FGFR1 (0.62) | FGFR1FGFR2FGFR3MEN1ESR1 | |
| SCHEMBL3794460 | 0.87 | TAAR1 (0.70) | FGFR1FGFR2FGFR3ENPP2TAAR1 | |
| SCHEMBL2948809 | 0.86 | ENPP2 (0.76) | FGFR1FGFR2FGFR3ESR1KMT2A | |
| SCHEMBL28241991 | 0.85 | ENPP2 (0.53) | FGFR1FGFR2FGFR3MEN1ESR1 | |
| SCHEMBL28247640 | 0.85 | TAAR1 (0.74) | FGFR1FGFR2FGFR3ENPP2TAAR1 | |
| SCHEMBL3791745 | 0.85 | LOXL2 (0.60) | FGFR1FGFR2FGFR3ENPP2TAAR1 | |
| SCHEMBL29400616 | 0.83 | TAAR1 (0.70) | ENPP2TAAR1HRH3AGXTCFD | |
| SCHEMBL43554 | 0.83 | TAAR1 (0.70) | ENPP2TAAR1HRH3AGXTCFD | |
| SCHEMBL2571691 | 0.83 | ABAT (0.84) | MEN1ESR1KMT2AENPP2ABAT | |
| SCHEMBL14213318 | 0.82 | TAAR1 (0.57) | FGFR1FGFR2FGFR3ENPP2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102596873-B | Novel trisphenol compound | HONSHU CHEMICAL IND | 2014-11-12 | — | — | CN | disclosed |
| EP-2764866-A1 | Inhibitors of nedd8-activating enzyme | IP Gesellschaft für Management mbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| EP-2764866-A1 | Inhibitors of nedd8-activating enzyme | IP Gesellschaft für Management mbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013021309-A1 | INTERMEDIATE AND PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | PFIZER LIMITED (GB) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013021309-A1 | INTERMEDIATE AND PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | PFIZER LIMITED (GB) | 2013-02-14 | — | — | WO | disclosed |
| CN-102596873-A | Novel trisphenol compound | HONSHU CHEMICAL IND | 2012-07-18 | — | — | CN | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007010356-A2 | PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| EP-1708991-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005080313-A9 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005080313-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | FGFR1 1992/4885FGFR2 1591/4885FGFR3 2944/4885 |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | SULT2A1, STS, SULT1A1 | FGFR1 552/4885FGFR2 692/4885FGFR3 1314/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | FGFR1 2015/4885FGFR2 2702/4885FGFR3 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.